StockMarketWire.com - ConvaTec Group has confirmed that, from 1 January, its four franchises will be led by Franchise Presidents who will report directly to the Group Chief Executive Officer and who will be members of the Executive Committee.

The Franchise Presidents will be responsible for leading the development and delivery of their worldwide strategic plans across all ConvaTec's markets, including the Marketing and R&D organisations within their Franchise.

They will be working closely with the key functional areas of ConvaTec such as Sales, Regional Marketing, Regulatory and Quality Assurance, Manufacturing and Supply Chain operations and Business Development, to ensure alignment and collaboration.

The Group said these changes will drive an enhanced focus on performance across the its businesses, leveraging the strong pipeline of new products and the Group's leading market positions.

The roles of the Regional Presidents and all other members of the Executive Committee will remain unchanged. The changes will be effective 1 January.

Advanced Wound Care will now be led by Peter Byloos, who is joining ConvaTec from the investment company Gimv.

Ostomy Care: Erik Zimmer will continue as VP & General Manager of the Ostomy Care Franchise and will join the Executive Committee, reporting to the Group Chief Executive. An announcement on the appointment of a President for the Ostomy Care Franchise will be made in due course. Continence and Critical Care: Frank Gehres, who is currently the Interim President of EMEA, has been appointed as President of the Continence and Critical Care Franchise. Mads Haugaard will report to Frank as Vice President and General Manager. Infusion Devices: John Lindskog will continue in his current role as President with responsibility for the Infusion Devices Franchise. Following these changes, Symeria Hudson, previously President Global Franchises and Innovation, will be leaving the Company with effect from 31 December 2017.




At 2:10pm: [LON:CTEC] ConvaTec Group Plc share price was +2.5p at 202p



Story provided by StockMarketWire.com